Congenital Heart Disease (CHD) Market Report 2025 – Market Size and Analysis

 At what pace is the congenital heart disease (chd) market growing, and what is its estimated value?

The congenital heart disease (CHD) market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.

The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.



Get Your Free Sample of The Global Congenital Heart Disease (CHD) Market Report:
Congenital Heart Disease (CHD) Market Report 2025

Which Market drivers have played a significant role in driving the congenital heart disease (chd) market?

The increase in maternal diabetes cases is expected to propel the growth of the congenital heart disease (CHD) market going forward. Maternal diabetes, or gestational diabetes mellitus (GDM), refers to diabetes that arises during pregnancy in women who did not have diabetes before conception. Maternal diabetes is caused by changes in lifestyle, including sedentary behavior and unhealthy dietary habits, and an overall rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants due to the high blood sugar levels affecting fetal heart development. The elevated glucose levels in the mother's blood can disrupt the normal development of the baby's heart, increasing the risk of CHD. For instance, in October 2023, according to the National Health Service a UK-based government department, adverse pregnancy outcomes in women diagnosed with type 2 diabetes in 2021 was 4.9% which increased to 6.6% in 2022. Therefore, the increase in maternal diabetes cases is driving the growth of the congenital heart disease (CHD) market.

What are the key segments within the congenital heart disease (chd) market?
The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types
2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis
3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications
4) By Age Group: Infants, Children, Adolescents, Adults
5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:
1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation
2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus
4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction


Order your report now for swift delivery
Congenital Heart Disease (CHD) Market Report 2025

Which key players are shaping the congenital heart disease (chd) market?

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

Which transformative trends will shape the congenital heart disease (chd) market landscape?

Major companies operating in the congenital heart disease market are developing non-surgical heart valves to improve patient outcomes and quality of life. Non-surgical heart valves, or transcatheter, are medical devices that treat heart valve diseases without needing traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. It is a groundbreaking, minimally invasive alternative to open-heart surgery for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. This system is the first FDA-approved valve designed for the right side, providing a non-surgical solution for patients with severe pulmonary valve regurgitation. The Harmony TPV System received U.S. FDA approval in 2021. It was reintroduced following a voluntary recall, demonstrating Medtronic's commitment to advancing solutions for congenital heart disease patients.

How do regional factors impact the congenital heart disease (chd) market, and which region is the largest contributor?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does The Congenital Heart Disease (CHD) Market Report 2025 Offer?

The congenital heart disease (chd) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Congenital heart disease (CHD) refers to a range of birth defects affecting the structure and function of the heart that are present at birth. These defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. The treatment for CHD depends on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

Purchase the exclusive report now to unlock valuable market insights:
Congenital Heart Disease (CHD) Market Report 2025

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: In-Depth Insights into the Chainsaws Market: Growth, Trends, and Opportunities for 2025-2034 - Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports - By The Business Research Company
Global Market Model: Global Market Intelligence Database